FDA Approves Expanded Liquid Biopsy Panel - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

  • By

  • Kathryn Wighton

  • May 20, 2026

  • 2 min

Share

Objective:

To inform about the FDA approval of the Guardant360 Liquid CDx assay for advanced cancer treatment selection.

Key Findings:
  • The assay is the largest FDA-approved liquid biopsy panel.
  • It combines genomic and epigenomic profiling to improve tumor detection.
  • The platform is based on AI-enabled technology and supports various cancer care stages.
Interpretation:

This approval signifies a significant advancement in precision oncology, providing clinicians with timely and comprehensive information for treatment decisions.

Limitations:
  • The assay's effectiveness may vary based on individual patient factors.
  • Coverage by insurers may not be universal across all regions.
Conclusion:

The Guardant360 Liquid CDx assay represents a major step forward in liquid biopsy technology, potentially improving treatment outcomes for patients with advanced cancers.

Original Source(s)

FDA Approves Expanded Liquid Biopsy Panel

  • by Kathryn Wighton

  • May 20, 2026

Related Content

Neurogenic progression may falter in MDD

Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.

Narrow DCIS Margins May Not Always Warrant Reexcision

An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.